Galderma’s Alastin Comes To Key Markets Across Asia Pacific

Galderma has launched its regenerative skincare brand Alastin across the JPAC region.

The brand recently launched in Taiwan, will soon launch in Japan, and has received approval to launch in Singapore and South Korea, with planned market introduction in September and November, respectively.

Officials say the expansion follows Alastin’s recent launches in China and Australia and underscores Galderma’s continued investment in JPAC, a region characterized by advanced skincare practices and rapid growth in injectable aesthetics.

By introducing Alastin, Galderma is expanding access to a holistic regenerative skincare portfolio designed to address some of today’s most significant aesthetic trends and needs, from an increased focus on skin quality and longevity, to growing concerns around menopause-related skin health, medication-driven weight loss and aging.

“Alastin sets a new standard in regenerative skin care, so we’re excited to bring it to patients and healthcare professionals in the JPAC region, where there is an ever-increasing demand for aesthetic procedures and peri-procedural care,” said Galderma’s Chief Scientific Officer, Alan. D. Widgerow. “As part of our commitment to delivering holistic regenerative skincare, the Alastin range is carefully curated to work synergistically with our Injectable Aesthetics portfolio, as well as daily skincare maintenance, enabling us to support patients with tailored solutions that address evolving needs.”

“Patients today expect skincare that goes beyond surface hydration,” said Dr. Rieko Tsubouchi, director of Ginza Skin Clinic, Japan. “They seek products that support skin function, renewal and long-term skin quality.”

Alastin offers a range of peri-procedural support and daily skincare products that amplify the skin’s natural regenerative abilities, supporting recovery and enhances visible outcomes of in-demand aesthetic procedures such as energy-based device and injectable treatments. Select Alastin products are powered by proprietary TriHex Technology, which uniquely combines peptide components that help clear aged, damaged collagen and elastin while simultaneously supporting the production of new, healthy collagen and elastin – a dual mechanism that underpins its regenerative approach. Restorative Skin Complex with TriHex+ supports the skin’s natural production of high molecular weight hyaluronic acid (HA), while further enhancing collagen and elastin production, contributing to long-term skin longevity.

Science-Driven Skincare Heritage

With more than 60 international dermatological publications and over 25 granted patents, Alastin is one of the most clinically studied skincare brands. In the United States it is the number one peri-procedural option and continues to be one of the fastest-growing global medical aesthetics skincare brands. It is powered by a proprietary peptide-based synergistic combination of ingredients and supported by real-world clinical experience demonstrating high levels of patient satisfaction, including improvements in radiance, recovery following procedures, and sustained hydration as well as overall skin resilience.

Nine products of The Alastin Skincare portfolio will be available in the JPAC region, including:

• Skin Nectar and INhance – both with TriHex Technology – developed for peri-procedural use to enhance visible outcomes and reduce recovery time;
• Restorative Skin Complex with TriHex+, Restorative Eye Complex with TriHex Technology and Restorative Neck Complex with TriHex Technology;
• Targeted serums formulated to address specific skin concerns: C-Radical Defense (an antioxidant serum that protects against environmental stressors), A-Luminate Brightening Serum (reduces the appearance of hyperpigmentation and discoloration for a more even skin tone) and HA Immerse Serum (enhances skin hydration); and
• Ultra Nourishing Moisturizer with TriHex Technology.